Impact of CRRT patterns on calcium levels in patients using citrate anticoagulants
Effects of Different Continuous Renal Replacement Therapy Patterns on Ionized Calcium in Patients With Citrate Anticoagulants Using Calcium-containing Replacement Solutions
This study is testing how different kidney treatment methods affect calcium levels in patients using a specific blood thinner called citrate.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | Fujian Provincial Hospital Academic / other |
| Locations | 1 site (Fuzhou, Fujian) |
| Trial ID | NCT06021080 on ClinicalTrials.gov |
What this trial studies
This observational cohort study investigates how different continuous renal replacement therapy (CRRT) methods, specifically veno-venous hemofiltration (CVVH) and continuous veno-venous hemodialysis (CVVHD), affect ionized calcium concentrations in patients undergoing regional citrate anticoagulation. Patients will be randomly assigned to one of the two CRRT methods and will switch to the alternative method in subsequent sessions. Key measurements will include pre-filter and post-filter ionized calcium levels, as well as other electrolyte and citrate dose data collected throughout the treatment. The study aims to clarify the relationship between CRRT patterns and calcium levels, which is crucial for patient safety and treatment efficacy.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who are receiving citrate anticoagulation for renal replacement therapy.
Not a fit: Patients who are pregnant, have severe liver dysfunction, or are experiencing significant hypoxemia or inadequate tissue perfusion may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the management of calcium levels in patients undergoing CRRT, potentially improving patient outcomes.
How similar studies have performed: While this approach is not widely tested, similar studies have explored the effects of anticoagulation methods on renal therapy outcomes, indicating potential for valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥ 18 years old; 2. Receiving citrate anticoagulation; 3. Obtain Informed consent from patients or next of kin. Exclusion Criteria: 1. Pregnant or lactating women; 2. Allergic to citrate anticoagulants; 3. Severe liver dysfunction (total bilirubin levels exceeding two times the normal range); 4. Hypoxemia (PaO2 \< 60 mmHg); 5. Inadequate tissue perfusion (blood pressure \< 90/60 mmHg despite high doses of vasoactive agents); 6. Hyperlactatemia (lactate\> 4 mmol/L); 7. Hypernatremia; 8. Estimated length of hospital stay \< 48h; 9. Participated in other studies.
Where this trial is running
Fuzhou, Fujian
- Fujian Provincial Hospital — Fuzhou, Fujian, China (Recruiting)
Study contacts
- Principal investigator: Han Chen, Ph.D., M.D. — Fujian Provincial Hospital
- Study coordinator: Han Chen, Ph.D., M.D.
- Email: hanchen.cn@icloud.com
- Phone: +86 591 88217010
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.